Hormonal
Higher postprandial endogenous GLP-1 release is positively correlated with hepatic and peripheral insulin sensitivity in individuals with class II/III obesity without diabetes, and this association persists one year after Roux-en-Y gastric bypass (RYGB).
For individuals with obesity, higher natural GLP-1 responses to meals are linked to better insulin sensitivity. While Roux-en-Y gastric bypass significantly amplifies this GLP-1 response, leading to improved metabolic health, the study suggests that the magnitude of this hormonal response is a key indicator of metabolic status. Non-surgical strategies that might support healthy incretin responses (though not explicitly detailed in this paper) could be beneficial, but the data strongly links the specific postprandial GLP-1 profile to insulin sensitivity.
Postprandial GLP-1 concentrations correlate with insulin sensitivity in subjects with class II/III obesity without diabetes before and 1 year after RYGB.
Why this rating
The study uses gold-standard hyperinsulinemic-euglycemic clamps and stable isotope tracers, though the sample size for the follow-up is small (n=10).
Source
The relation between postprandial glucagon-like peptide-1 release and insulin sensitivity before and after bariatric surgery in humans with class II/III obesity
Pim W. Gilijamse et al. · Surgery for Obesity and Related Diseases · 2021
DOI 10.1016/j.soard.2021.04.022
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →